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Mast cell activation syndrome (MCAS) is a disorder in which patients experience symptoms and signs attributable to inappropriate
mast cell activation and mediator release. Multiorgan involvement in patients can result in significant morbidity and possible
mortality. Limited literature exists regarding anesthetic management of patients with MCAS. We report a case of vaginal delivery
with neuraxial labor analgesia in a parturient with this condition and highlight the importance of multidisciplinary planning for
uneventful outcomes. Stress can trigger life-threatening symptoms, and counseling is important to allay patients’ fears. Optimum
medical control, adequate premedication, avoidance of triggers, and preparedness to treat serious mediator effects are key. We
review MCAS and discuss anesthetic considerations for patients with this mast cell disorder.
1. Introduction
Mast cell activation syndrome (MCAS) is a condition in
which patients experience recurrent and episodic symptoms
of mast cell degranulation. Patients with this disorder appear
to represent a growing proportion of the mast cell disorder
patient population [1, 2]. There is paucity of literature on this
subject relevant to an anesthesiologist. Our pregnant patient
had symptomatology suggestive of a mast cell mediated
disorder with significant suffering and disability. Written
consent was taken from her for publication of this case
report.
2. Case
A 24-year-old female G3P2 was admitted for induction
of labor at 39 weeks’ gestation. Her pregnancy had been
uneventful except for a diagnosis of gestational hyperten-
sion (diet controlled). During a scheduled obstetric visit at
39 weeks, she met criteria for preeclampsia with resulting
hospitalization. She had history of 2 prior vaginal deliveries
with neuraxial analgesia, both following induction of labor
for preeclampsia.
Her medical history was significant for iron deficiency
anemia (received iron infusions for treatment), hypothy-
roidism (controlled with levothyroxine), celiac disease, and a
recent diagnosis ofMCAS. A fewmonths after the birth of her
second child 2 years ago, she began experiencing potentially
life-threatening reactions. These reactions typically followed
a pattern of abdominal discomfort and diarrhea followed by
extremity and facial swelling, hives, and throat itching. Trig-
gers included certain foods, drugs, and physical or emotional
stress. The patient reported frequent emergency room (ER)
visits for this condition. Self-administration of epinephrine
autoinjector and diphenhydramine resulted in relief of symp-
toms during most episodes. Occasional treatment with cor-
ticosteroids was necessary without need for overt resus-
citative measures related to fluid replacement or airway
management. A treatment regimen for MCAS was started
and avoidance of known triggers including nonsteroidal
anti-inflammatory drugs (NSAIDs) andhistamine-rich foods
was advised. Her surgical history included a bone marrow
biopsy, esophagogastroduodenoscopy, and colonoscopy with
no complications. Her physical examination was significant
for obesity (body mass index 33) and an unremarkable back
and airway examination.
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Table 1: Classification of disorders associated with mast cell activation∗.
PRIMARY SECONDARY IDIOPATHIC
(i) Clonal mast cell disorders (e.g.,
mastocytosis)
(ii) Monoclonal mast cell activation syndrome
(i) Allergic disorders (e.g., asthma, rhinitis)
(ii) Mast cell activation associated with
inflammatory or neoplastic disorders
(iii) Physical urticaria
(iv) Chronic autoimmune urticaria
(i) Urticaria
(ii) Angioedema
(iii) Anaphylaxis
(iv) Mast cell activation syndrome(MCAS)†
∗†The term MCAS has been used interchangeably in the literature to denote both the umbrella term and idiopathic MCAS [4, 17].
During routine obstetric visits, she repeatedly requested
elective cesarean delivery with general anesthesia due to con-
cern for allergic reactions during labor. Our obstetric team
sawno contraindication to a vaginal delivery and after intense
counseling including discussion with an anesthesiologist she
agreed to a trial of labor with early neuraxial analgesia. A
multidisciplinary approach involving an obstetrician, anes-
thesiologist, hematologist, allergist, neonatologist, nursing
personnel, and dietician was used to formulate a plan for
delivery. A premedication regimen prior to delivery, with
availability of an anaphylaxis treatment kit and resuscitation
equipment at bedside, was planned. In addition to the existing
daily regimen of cetirizine, famotidine, and montelukast,
she was informed to start prednisone 60mg daily about 48
hours prior to estimated date of delivery. Low-histamine and
gluten-free diet precautions were to be followed during her
hospital stay.
Following induction of labor with a Foley transcervical
balloon and vaginal misoprostol, she requested epidural
analgesia. Doses of 125mg methylprednisolone and 50mg
diphenhydramine were given intravenously as premedica-
tion, and the procedure was accomplished with good pain
relief. After approximately 4 hours, she complained of
increasing pain secondary to uterine contractions. Examina-
tion of her lumbar area revealed a dislodged epidural cath-
eter due to unclear reasons. The epidural procedure was
repeated after again administering a prophylactic dose of
50mg diphenhydramine, and catheter placement was done
uneventfully. Alcohol based chlorhexidinewas used unevent-
fully for skin antisepsis both times. She received 0.2% ropiva-
caine infusion through the epidural catheter with adequate
pain relief. Oxytocin was used for augmentation of labor
with delivery of a healthy neonate without complications.
Her postpartum hospital stay was complicated by an unusual
episode of abdominal discomfort and itchy throat, after
exposure to odor from a citrus fruit (histamine-rich food),
consumed by the other patient in her shared room. She was
immediately given 50mg diphenhydramine with resolution
of symptoms and shifted to a single occupancy room. Our
patient was discharged home on the third day following
delivery without any other complications.
3. Discussion
Mast cells are an important part of our body’s immune
system, originating from the bone marrow and participating
in inflammatory processes with production of mediators
[3]. A certain level of mast cell activation is physiological
and necessary for maintenance of homeostasis [4]. Mast cell
activation syndromes is an umbrella term used to describe
disorders in which recurrent and inappropriate mast cell
activation and release ofmediators occurs, causing symptoms
associated with multiple organ systems.
The term was introduced to propose a global unifying
classification of all mast cell activation disorders, with divi-
sion into primary (proliferation of abnormal mast cells),
secondary (normal mast cells activated in response to a
microenvironmental trigger), and idiopathic (no evidence of
primary or secondary cause) as shown in Table 1 [1, 5].
3.1. Presentation and Diagnosis. Typical symptoms and signs
are listed in Table 2 [6].
Proposed diagnostic criteria for MCAS are listed in
Table 3 [1].
Mast cells can be activated through both IgE and non-
IgE dependent mechanisms with release of mediators such
as histamine, tryptase, leukotrienes, and prostaglandins.
Activation typically occurs in response to triggers, although
none may be identified [7]. Clinical manifestations occur
secondary to tissue responses to these mediators.
Our patient had episodic symptoms throughout her
pregnancy with no disorder identified that could account for
them. A bonemarrow biopsy done had shown no evidence of
mast cell disease, despite some abnormalities in megakary-
ocyte clustering and reticulum fibrosis. An elevated serum
tryptase was found during an ER visit, with normal serum
tryptase and blood histamine level in between episodes.
With known primary and secondary causes ruled out, a
potential diagnosis of idiopathic MCAS was made based on
diagnostic criteria. A thorough workup was deferred until
after delivery. Patients are often known to undergo extensive
medical evaluation to determine an etiology, with a goal
to find a yet-to-be identified endogenous or environmental
stimulus or mast cell defect.
3.2. Treatment. Avoidance of exposure to identifiable trig-
gers and antimediator therapy, including medications that
prevent mast cell degranulation, form the basis of treat-
ment. Multidrug therapy, such as H-1 and H-2 receptor
antagonists, mast cell stabilizers, and leukotriene receptor
antagonists are used in varying combinations to achieve
control. Epinephrine autoinjector and antihistamine drugs
are typically used by patients for breakthrough degranulation,
with more aggressive treatment done in a hospital setting if
necessary. Recently, omalizumab has been shown to prevent
Case Reports in Anesthesiology 3
Table 2: Common symptoms and signs of MCAS.
Dermatologic Flushing, pruritus, hives
Cardiovascular Near syncope or syncope, palpitations, chest pain, dysrhythmias, hypotension, hypertension
Pulmonary Cough, wheezing
Eyes, ear, nose, throat Post nasal drip, inflammation (conjunctivitis, rhinitis, sinusitis, pharyngitis, laryngitis), throat itching andswelling
Neurologic Headache, seizures, tremors
Psychiatric Cognitive dysfunction, memory difficulties, anxiety, depression, psychoses
Gastrointestinal Nausea, vomiting, reflux, constipation, diarrhea, abdominal pain, malabsorption
Musculoskeletal Bone or muscle pain, arthritis, myositis
Immunologic Types I, II, III, and IV hypersensitivity reaction
Table 3: Proposed diagnostic criteria for MCAS.
(1) Episodic symptoms of mast cell mediator release involving
≥2 organ systems
(2) Appropriate response to antimediator therapy
(3) Documented increase in validated systemic markers of mast
cell activation during episode (e.g., serum tryptase or urinary
markers such as histamine metabolites, prostaglandin D2 or its
metabolite, and leukotriene E4)
(4) Primary and secondary causes ruled out
symptoms and reduce adverse events. Cytoreductive and
immunomodulating therapies are tried in some cases.
3.3. Anesthetic Considerations. Little is known about the per-
ioperative management of patients with MCAS. The main
anesthetic concern is avoidance of mast cell mediator release.
In addition to workup for evaluation of comorbidities, a
multidisciplinary plan for perioperative management with
involvement of the patient is necessary to lessen concerns.
Medications taken for MCAS should be continued up to the
day of surgery. A premedication regimen of H-1 and H-2
receptor antagonists and corticosteroids are recommended
before invasive procedures including those requiring anes-
thesia, the goal being reduction and blockade of mediators
that can cause life-threatening reactions such as anaphylaxis
[8]. Benzodiazepines are valuable in reducing anxiety, a
known trigger.
Deviation from routine anesthetic techniques is not nec-
essarily warranted although central and peripheral neuraxial
techniques reduce risk of multiple drug administration [9].
Adequate premedication, avoidance of triggers, and emer-
gency preparedness are key. A list of possible perioperative
triggers is shown in Table 4 [10]. Judicious use and increased
vigilance are mandatory if such triggers cannot be avoided.
Data on adverse drug reactions and mast cell disease is
scarce. Knowledge of drugs that can cause histamine release
is key, with avoidance suggested based on theoretical assump-
tions. Drugs which are suspected to have caused previous
reactions should be avoided [9].
Preprocedural skin testing is not recommended unless a
previously documented hypersensitivity reaction exists [11].
Patients may experience reactions to medications they have
tolerated previously. With limited knowledge of causative
mechanisms, vigilance is key. Usage of perioperative drugs in
this context is described in Table 5 [8, 10–14].
Serious perioperative reactions caused by mast cell medi-
ators can be anaphylactic or anaphylactoid. Occurrence of
such reactions is likely to be higher as compared to the general
population. Clinical features mainly involve the skin and
cardiovascular and respiratory systems. Management should
focus on withdrawing the offending agent, interrupting the
effects of themediators already released, and preventingmore
mediator release. Symptomatic and supportive treatment
include oxygen, H-1 and H-2 antagonists, corticosteroids,
bronchodilators, epinephrine, fluids, and airway resuscitation
[10]. Measurement of serummediators (e.g., tryptase) during
the episode, with identification and testing of all exposures,
should be done to determine etiology, although results are
often negative or insufficiently reliable.
3.4. MCAS and Pregnancy. Data from studies on pregnancy
and delivery in patients with mast cell disorders is reas-
suring [10, 15]. Mast cells exhibit a beneficial function in
pregnancy by contributing to implantation, placentation, and
fetal growth. Excessive release of mediators can be associated
with pretermdelivery.Although the use of systemic treatment
should be limited or even avoided in pregnancy, optimum
management is recommended for maternal and fetal well-
being. With appropriate medical control, there is no con-
traindication to pregnancy [16]. Vaginal delivery with early
neuraxial analgesia is permissible, in the absence of an obstet-
ric indication for cesarean section. Similar perioperative
considerations apply for eithermode of delivery. Practitioners
should be aware of possible sedation in the newbornwhenH-
1 antagonists are used directly before delivery.
4. Conclusion
MCAS is an area of ongoing research. Our patient had
an uneventful pregnancy, labor, and delivery despite the
increased morbidity from MCAS. At 3 months’ postpartum,
she continued to report frequent allergic reactions and
currently follows up with a mast cell disorders specialist.
With this review, we attempt to add to the limited anesthesia
literature regarding MCAS. Knowledge of this condition
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Table 4: Perioperative triggers and treatments.
Type Stressor Treatment
Psychological Anxiety, emotional stress Pharmacologic, quiet environment
Mechanical
Pressure (tourniquet and BP cuff), friction (tape)
surgery (GI tract a rich source of mast cells)
Minimize operative time, optimal
positioning,
Pain Multimodal analgesia
Pharmacologic Histamine releasing drugs Avoid
Temperature Hypothermia, hyperthermia, change in temperature
Heat maintenance devices, warm
environment, warm intravenous and
irrigation fluids
Infection Bacterial, viral, fungal As necessary
Foods, odors Histamine-rich foods, odors (food, perfumes) Avoid, single occupancy room
BP: blood pressure and GI: gastrointestinal.
Table 5: Perioperative drugs and mast cell diseasea.
Class Drug Usage in mast cell disorders
Hypnotic/sedative
agents
Propofolb, dexmedetomidine, etomidate, ketamineb Acceptable
Methohexital, thiopental Thiopental causes histamine release
Inhalational
anesthetics
Halogenated (isoflurane, sevoflurane, desflurane), nitrous
oxide Acceptable
Benzodiazepinesb Midazolam, diazepam Acceptable
Opioidsc
Morphine, meperidine, codeine Causes histamine release
Hydromorphone, fentanyl, sufentanil, alfentanil,
remifentanil, buprenorphine Acceptable
Nonopioid analgesics
Acetaminophen Acceptable
NSAIDs (ketorolac, nefopam) Causes overproduction of leukotrienes (a mastcell mediator)
Neuromuscular
blocking agents
Depolarizing NMBA (succinylcholine) Acceptable
Nondepolarizing aminosteroidsc (rocuronium,
vecuroniumb pancuronium) Acceptable
Nondepolarizing benzylisoquinolines (atracurium,
mivacurium, cisatracurium)
Atracurium and mivacurium cause histamine
release
Reversal of
neuromuscular
blockade
Neostigmine, sugammadex Acceptable
Local anestheticsc Amides and esters Acceptable
Antisepticsc Alcohol, chlorhexidine, povidone-iodine Acceptable
Intravenous fluids Crystalloids, colloids, albumin, gelatin, hydroxyethylstarchc Acceptable
Common labor and
delivery drugs
Oxytocin, prostaglandins, methylergonovine, tocolytic
agent (terbutaline)
Acceptable, though role of prostaglandins in
causing or worsening reactions is unclear
Antibioticsc Penicillins, cephalosporins, sulfonamides, vancomycin,polymyxin B, clindamycin, fluoroquinolones
Vancomycin and polymyxin B can cause
histamine release
Miscellaneous
Adenosine, atropine, glycopyrrolate, ondansetron,
beta-blockers, ACEI, protamine, aprotinin (fibrin glue),
blood transfusion, dyes, contrast media, and latexc
Acceptable; adenosine and protamine can cause
histamine release; beta-blockers can attenuate the
effect of epinephrine in anaphylaxis; ACEI can
augment an anaphylactic reaction
NSAIDs: nonsteroidal anti-inflammatory drugs; NMBA: neuromuscular blocking agents; ACEI: angiotensin converting enzyme inhibitors. aDrugs associated
with histamine release should be avoided if another equally effective drug can be used; alternatively, theymust be administered slowly. bDrugs reported to cause
in vitro histamine release from human mast cells. cDrugs and products associated with high incidence of hypersensitivity reactions in the general population
do not need to be avoided unless a previously documented sensitivity exists.
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with appropriate planning and preparation will help ensure
optimal outcomes.
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